HelmholtzZentrum munich
WCMC

Connecting genetic risk to disease endpoints through the human blood plasma proteome

ONLINE SUPPLEMENTARY INFORMATION

Home
Ideogram
Loci
Network view
Proteome annotation
Help
Locus annotations

Locus 156

Top associations per target

Target cis/​trans Study SNP SNP location Maj/​min allele MAF N βinv seinv Pinv fclog Plog Praw
PPID cis Discovery rs8396 4:159,630,817 T/C 0.29 988 0.501 0.046 3.4×10-26 1.250 5.1×10-23 1.3×10-29
PPID cis Replication rs55936281 4:159,648,596 G/A 0.20 337 0.126 0.049 0.01 1.120 0.064 1.2×10-9

 

Regional association plots

Peptidyl-prolyl cis-trans isomerase D (PPID)

Download the association data used to generate this plot

 

Boxplots and histograms for top associations

Peptidyl-prolyl cis-trans isomerase D (PPID)

inverse-normalized probe levels log2 transformed probe levels raw probe levels
Discovery study
Replication study

Peptidyl-prolyl cis-trans isomerase D (PPID)

Target (abbrv.) PPID
Target (full name) Peptidyl-prolyl cis-trans isomerase D
Somalogic ID (Sequence ID) SL007373 (5202-4_3)
Entrez Gene Symbol PPID
UniProt ID Q08752
UniProt Comment
  • PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Proposed to act as a co-chaperone in HSP90 complexes such as in unligated steroid receptors heterocomplexes. Different co-chaperones seem to compete for association with HSP90 thus establishing distinct HSP90-co-chaperone-receptor complexes with the potential to exert tissue-specific receptor activity control. May have a preference for estrogen receptor complexes and is not found in glucocorticoid receptor complexes. May be involved in cytoplasmic dynein-dependent movement of the receptor from the cytoplasm to the nucleus. May regulate MYB by inhibiting its DNA-binding activity. Involved in regulation of AHR signaling by promoting the formation of the AHR:ARNT dimer; the function is independent of HSP90 but requires the chaperone activity. Involved in regulation of UV radiation-induced apoptosis. Promotes cell viability in anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+ ALCL) cell lines. May be involved in hepatitis C virus (HCV) replication and release.
Pathway Interaction Database
  • C-MYB transcription factor network

All locus annotations are based on the sentinel SNP (rs8396) and 15 proxy variant(s) that is/are in linkage disequilibrium r2 ≥ 0.8. Linkage disequilibrium is based on data from the 1000 Genomes Project, phase 3 version 5, European population and was retrieved using SNiPA's Block Annotation feature.
Download the detailed results of SNiPA's block annotation (PDF)

Linked genes


Warning: count(): Parameter must be an array or an object that implements Countable in /var/www/html/pGWAS/locuscard.php on line 327
Genes hit or close-by
  • ETFDH electron-transferring-flavoprotein dehydrogenase
  • U3
  • PPID peptidylprolyl isomerase D
eQTL genes
  • ETFDH electron-transferring-flavoprotein dehydrogenase
  • U3
  • PPID peptidylprolyl isomerase D

 

Results from other genome-wide association studies

Trait P Study Source
Blood metabolite ratios 2×10-57 24816252 (PMID) GWAS Catalog via SNiPA
decanoylcarnitine 8.7×10-38 24816252 (PMID) gwas.eu via SNiPA
Blood metabolite levels 1×10-31 24816252 (PMID) GWAS Catalog via SNiPA
C14:1-OH / C10 3.5×10-24 20037589 (PMID) GRASP2 metabQTL
Metabolite levels 4×10-24 20037589 (PMID) GWAS Catalog via SNiPA
C7-DC / C10 2.9×10-22 20037589 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(palmitate (16:0)) 4.8×10-20 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(oleate (18:1n9)) 6.5×10-20 21886157 (PMID) GRASP2 metabQTL
C14:1-OH / C8 1×10-19 20037589 (PMID) GRASP2 metabQTL
Serum ratio of (octanoylcarnitine)/(palmitate (16:0)) 5.5×10-19 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(palmitoylcarnitine) 7.2×10-19 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(oleoylcarnitine) 8×10-19 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(stearate (18:0)) 1.1×10-18 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (octanoylcarnitine)/(oleate (18:1n9)) 1.1×10-18 21886157 (PMID) GRASP2 metabQTL
C7-DC / C8 1.4×10-18 20037589 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(linolenate [alpha or gamma; (18:3n3 or 6)]) 2.5×10-18 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(eicosenoate (20:1n9 or 11)) 3.6×10-18 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (octanoylcarnitine)/(stearate (18:0)) 4.7×10-18 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(myristate (14:0)) 5.3×10-18 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (10-heptadecenoate (17:1n7))/(decanoylcarnitine) 6.8×10-18 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(glycerol) 1.4×10-17 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (10-undecenoate (11:1n1))/(decanoylcarnitine) 1.7×10-17 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(laurate (12:0)) 2×10-17 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (decanoylcarnitine)/(linoleate (18:2n6)) 2.1×10-17 21886157 (PMID) GRASP2 metabQTL
C14:2-OH / C10 4.2×10-17 20037589 (PMID) GRASP2 metabQTL
C12:1 / C10 1.2×10-16 20037589 (PMID) GRASP2 metabQTL
C14 / C10 5.2×10-16 20037589 (PMID) GRASP2 metabQTL
C10:2 / C10 6.4×10-16 20037589 (PMID) GRASP2 metabQTL
C10 / C7-DC 6.5×10-16 20037589 (PMID) GRASP2 metabQTL
C16 / C10 6.6×10-16 20037589 (PMID) GRASP2 metabQTL
C16:1-OH / C10 1.2×10-15 20037589 (PMID) GRASP2 metabQTL
Serum concentration of octanoylcarnitine 1.4×10-15 21886157 (PMID) GRASP2 metabQTL
C10 / C12:1 1.6×10-15 20037589 (PMID) GRASP2 metabQTL
Serum concentration of decanoylcarnitine 5.5×10-15 21886157 (PMID) GRASP2 metabQTL
C10 / C14:1-OH 6×10-15 20037589 (PMID) GRASP2 metabQTL
Metabolic traits 6×10-15 21886157 (PMID) GWAS Catalog via SNiPA
C10 / C10:1 6.8×10-15 20037589 (PMID) GRASP2 metabQTL
C14:2-OH / C8 1.8×10-14 20037589 (PMID) GRASP2 metabQTL
C16:2-OH / C10 3.6×10-14 20037589 (PMID) GRASP2 metabQTL
C16:1 / C10 1.2×10-13 20037589 (PMID) GRASP2 metabQTL
C16:1-OH / C8 2×10-13 20037589 (PMID) GRASP2 metabQTL
C10:2 / C8 2.7×10-13 20037589 (PMID) GRASP2 metabQTL
C16 / C8 6.3×10-13 20037589 (PMID) GRASP2 metabQTL
C10:1 / C10 7.9×10-13 20037589 (PMID) GRASP2 metabQTL
C14:1 / C10 9.8×10-13 20037589 (PMID) GRASP2 metabQTL
C18:1 / C10 1.2×10-12 20037589 (PMID) GRASP2 metabQTL
H1 / C10 1.6×10-12 20037589 (PMID) GRASP2 metabQTL
C14 / C8 2.1×10-12 20037589 (PMID) GRASP2 metabQTL
C10 / C10:2 2.4×10-12 20037589 (PMID) GRASP2 metabQTL
C10 / C16:2 2.8×10-12 20037589 (PMID) GRASP2 metabQTL
C10 / C14:2-OH 3.5×10-12 20037589 (PMID) GRASP2 metabQTL
C10 / C14 3.7×10-12 20037589 (PMID) GRASP2 metabQTL
C12 / C7-DC 3.7×10-12 20037589 (PMID) GRASP2 metabQTL
C6(C4:1-DC) / C10 3.8×10-12 20037589 (PMID) GRASP2 metabQTL
C16-OH / C10 4.3×10-12 20037589 (PMID) GRASP2 metabQTL
Gln-PTC / C10 4.8×10-12 20037589 (PMID) GRASP2 metabQTL
C16:2 / C10 8.3×10-12 20037589 (PMID) GRASP2 metabQTL
C7-DC / C12 8.7×10-12 20037589 (PMID) GRASP2 metabQTL
C5:1 / C10 1.1×10-11 20037589 (PMID) GRASP2 metabQTL
C10 / C6(C4:1-DC) 1.4×10-11 20037589 (PMID) GRASP2 metabQTL
His-PTC / C10 1.6×10-11 20037589 (PMID) GRASP2 metabQTL
Phe-PTC / C10 1.6×10-11 20037589 (PMID) GRASP2 metabQTL
C14:1-OH / C12 1.8×10-11 20037589 (PMID) GRASP2 metabQTL
C16:2-OH / C8 1.9×10-11 20037589 (PMID) GRASP2 metabQTL
Val-PTC / C10 2×10-11 20037589 (PMID) GRASP2 metabQTL
PC ae C44:5 / C10 2.4×10-11 20037589 (PMID) GRASP2 metabQTL
C10 / C12 2.8×10-11 20037589 (PMID) GRASP2 metabQTL
PC aa C34:1 / C10 3.3×10-11 20037589 (PMID) GRASP2 metabQTL
C10 / C16:1 3.8×10-11 20037589 (PMID) GRASP2 metabQTL
Trp-PTC / C10 4.5×10-11 20037589 (PMID) GRASP2 metabQTL
C16:1 / C8 4.8×10-11 20037589 (PMID) GRASP2 metabQTL
PC aa C36:4 / C10 5.1×10-11 20037589 (PMID) GRASP2 metabQTL
C10 / C16:1-OH 5.6×10-11 20037589 (PMID) GRASP2 metabQTL
Serum ratio of (hexanoylcarnitine)/(oleate (18:1n9)) 3.2×10-9 21886157 (PMID) GRASP2 metabQTL
C10 4.9×10-9 20037589 (PMID) GRASP2 metabQTL
Gene expression of ETFDH///C4orf46 in blood 5.7×10-9 21829388 (PMID) GRASP2 eQTL
Serum ratio of (eicosenoate (20:1n9 or 11))/(hexanoylcarnitine) 6.8×10-9 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (hexanoylcarnitine)/(palmitate (16:0)) 7×10-9 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (hexanoylcarnitine)/(stearate (18:0)) 2.2×10-8 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (hexanoylcarnitine)/(linolenate [alpha or gamma; (18:3n3 or 6)]) 3.1×10-8 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (10-heptadecenoate (17:1n7))/(hexanoylcarnitine) 6.5×10-8 21886157 (PMID) GRASP2 metabQTL
cg21591693 (chr4:159647806) 1.1×10-7 10.1101/033084 (DOI) BIOS QTL cis-meQTLs
Serum ratio of (eicosenoate (20:1n9 or 11))/(laurylcarnitine) 2.8×10-7 21886157 (PMID) GRASP2 metabQTL
Serum ratio of (laurylcarnitine)/(oleoylcarnitine) 4.9×10-7 21886157 (PMID) GRASP2 metabQTL
C8 1.9×10-6 20037589 (PMID) GRASP2 metabQTL
Gene expression of ETFDH (probeID ILMN_540736) in whole blood 3.4×10-6 22692066 (PMID) GRASP2 eQTL
SM (OH) C24:1 5.6×10-6 20037589 (PMID) GRASP2 metabQTL
Differential exon level expression of PPID [probe 2791544] in brain cortex 7.1×10-6 19222302 (PMID) GRASP2 eQTL
Gene expression of PPID in normal prepouch ileum 1.9×10-4 23474282 (PMID) GRASP2 eQTL
SM (OH) C22:1 2.7×10-4 20037589 (PMID) GRASP2 metabQTL
PC ae C38:1 3.1×10-4 20037589 (PMID) GRASP2 metabQTL